Commentary: The equitable pathway

Compassionate access policies in the U.S. are fraying the ties between patients, and the drug companies, physicians and regulators that are essential for medical progress.

Now that the Josh Hardy case has let the social media genie out of the bottle, it is urgent that these groups, as well as lawmakers, work together to quickly create a system that is seen by the public as a fair way to adjudicate complex interests that can be both in conflict and legitimate (see Cover Story). ...